Dermtech

DermTech’s mission is to transform the practice of dermatology through more accurate diagnosis and treatment, and the elimination of unnecessary surgery, leading to improved patient care and lower costs. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel.

Dermtech. DERMTECH, INC. Condensed Consolidated Balance Sheets (in thousands, except share and per share data) (Unaudited) June 30, 2020 December 31, 2019 DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive diagnostic tests to diagnosis skin cancer and related conditions in the United States. More Details. Rewards. Revenue is forecast to grow 51.32% per year. Revenue grew by 83.7% over the past year. DermTech presently has a consensus target price of $22.00, indicating a potential upside of 107.94%. As a group, “Medical laboratories” companies have a potential upside of 14.91%. DermTech (NASDAQ: DMTK) is one of 37 public companies in the “Medical laboratories” industry, but how does it compare to its rivals? We will compare DermTech to related companies based on the strength of its profitability, risk, dividends, earnings, valuation, analyst recommendations and institutional ownership. Analyst Ratings This is a breakdown of recent recommendations and […]

For the second quarter, DermTech had an EPS of $0.58, compared to year-ago quarter EPS of $0.84. At the moment, the stock has a 52-week-high of $16.95 and a 52-week-low of $4.52. DermTech closed. DermTech (NASDAQ: DMTK) is one of 37 publicly-traded companies in the “Medical laboratories” industry, but how does it compare to its peers? We will compare DermTech to related companies based on the strength of its institutional ownership, valuation, analyst recommendations, earnings, profitability, dividends and risk. Volatility and Risk DermTech has a beta of 0.77, meaning […] DermTech presently has a consensus price target of $22.00, indicating a potential upside of 114.63%. As a group, “Medical laboratories” companies have a potential upside of 13.84%. Given DermTech’s stronger consensus rating and higher probable upside, research analysts clearly believe DermTech is more favorable than its competitors. DermTech to Participate in Upcoming Investor Conferences Sep. 3, 2020 at 4:01 p.m. ET on BusinessWire - BZX DermTech, Inc. Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Find the latest DermTech, Inc. (DMTK) stock quote, history, news and other vital information to help you with your stock trading and investing. DermTech A pain-free, adhesive patch that can detect whether your mole has the genes found in #melanoma at its earliest stages. Click👇to learn more about posts linkin.bio/dermtech Dermtech. Beautiful skin doesnt come from makeup – Beautiful skin comes from a great esthetinain. Primary Menu. Home; About Us; Contact Us; Search for: About Us. Owner, Cynthia Fleming, is a licensed esthetician instructor in the State of Texas. She has seven years of experience and knowledge in skin care and in the operation of esthetic. DermTech, La Jolla. 478 likes · 337 talking about this · 10 were here. DermTech is a commercial stage, genomic based, health technology company with a non-invasive gene expression platform for...

DermTech PLA Included in Peer Review Article of Novel Molecular Technologies for Melanoma Management with Potential to Address Current Gaps in Diagnostic Accuracy and Prognostication. May 13, 2020 DermTech, Inc. Reports First Quarter 2020 Financial Results and Provides Corporate Update. DermTech Inc is an emerging growth molecular diagnostic company. The company is engaged in marketing and developing novel non-invasive genomic tests to aid in the diagnosis of various skin. DermTech develops and commercializes qPCR assays for skin samples collected non-invasively using adhesive tape biopsy methods. The Company’s assays can analyze multiple gene targets to assess their level of RNA expression. The Company anticipates providing these assays through a CLIA certified laboratory located in San Diego. DermTech is the global leader in molecular dermatology. Our patented technology allows the analysis of skin biopsy samples collected non-invasively using an adhesive patch. Using this technology, we market and develop non-invasive gene expression tests to aid the clinical diagnosis of skin cancer, to assess inflammatory diseases, and to.

DermTech is a San Diego based molecular diagnostics company focused on the early detection of skin cancer enabled by a cutting edge non-invasive genomics platform; On August 29, 2019, Constellation Alpha Capital and DermTech underwent a merger and concurrent PIPE transaction at a price of $6.50 per share. On Mar 2, 2020, DMTK raised an additional $65 million at a price of $10.50 per share DermTech has developed a proprietary process to extract RNA from skin tissue samples collected non-invasively, using an adhesive patch. DermTech’s innovative platform technology uses the precision of genomics to enhance accuracy of diagnosis, eliminate unnecessary surgery, optimize treatment plans and lower health care costs. The DermTech PLA is a pain-free, adhesive patch that looks for the genes found in melanoma. The test is easy and takes only a few minutes. Your doctor can perform the test in their office or may decide that a telemedicine visit is more appropriate. Completely Online Access from anywhere Earn Certification Credential satisfies MU requirement Efficient Averages ~ 20 hours to complete About ACDTThe Association of Certified Dermatology Techs (ACDT) was established in 2012 to provide education and certification to those working in the supportive roles of clinical dermatology. In the past, the role of 'dermatology nurse' was traditionally.

DermTech | 2,875 followers on LinkedIn | ENHANCE EARLY DETECTION BY GETTING THE WHOLE PICTURE | DermTech is the global leader in molecular dermatology, bringing precision medicine to the diagnosis.